Almost 40 European, national, and regional industry organisations have joined forces to underline the urgent need for Biotech Act II, calling for a bold, market‑focused push in biomanufacturing across Europe.

 

A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative. Meanwhile, global competitors including the United States, India, and China are treating biomanufacturing as a top strategic priority. The groups say a strong EU Biotech Act II is essential to boost competitiveness, secure resilient value chains, and create high-quality employment across the continent.

 

While the EU Biotech Act Part I, which primarily targets health, has driven innovation, the paper highlights a critical gap in scaling up innovation to industrial levels across all sectors.

 

The signatories pledge to continue collaborating to advance a shared vision for Europe’s industrial future, ensuring biomanufacturing delivers long-term growth and resilience.

 

Claire Skentelbery, Director General of EuropaBio, said: “A Biotech Act II dedicated to biomanufacturing is the missing piece of the puzzle for the EU’s global competitiveness from this vital technology. It is essential that we empower all sectors with a thriving EU market, cutting edge capability and ensuring that it is the logical next investment for companies in our champion sectors. 

 

"We must create our own destiny for biomanufacturing, rather than watching it being delivered elsewhere and the job is not yet done.”